DRG Epidemiology’s coverage of cystic fibrosis (CF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of CF for…
DRG Epidemiology’s coverage of cystic fibrosis (CF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of CF for…
DRG Epidemiology’s coverage of cystic fibrosis (CF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of CF for…
With more than a dozen disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS), the treatment journey for MS patients is varied and complex. To date, the MS market has…
Glomerulonephritis (GN) is a broad term covering various conditions involving injury and inflammation of the glomerulus, which plays an important role in the filtration of blood in the kidney. As…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Pfizer’s Xeljanz is the first-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States and the first targeted oral therapy to launch for the moderate to severe UC…
KEY BENEFITS AND USESPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Trigeminal neuralgia (TN) is a rare and painful disorder, usually triggered by innocuous stimuli, resulting in paroxysmal neuropathic facial pain in the regions served by the trigeminal nerve…
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma patient populations covering 171 countries and more than…
DRG Epidemiology’s coverage of urothelial cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of urothelial cancer for each…
DRG Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of glioma for each…
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key Acute Lymphoblastic Leukemia populations covering 171 countries and more than…
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key glioma patient populations covering 171 countries and more than 99% of the…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic myeloid leukemia patient populations covering 171 countries and…